| Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma (NCT03613259) | OHSU Knight Cancer Institute | 2020-06-01 |
| Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas (NCT02357810) | Northwestern University | 2015-03-21 |
| TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery (NCT02180698) | Fred Hutchinson Cancer Center | 2014-11-17 |
| NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (NCT02059850) | Fred Hutchinson Cancer Center | 2014-07-01 |
| Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma (NCT02048722) | Northwestern University | 2014-06-13 |
| (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas (NCT01949506) | Medical College of Wisconsin | 2013-09-24 |
| A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (NCT01782313) | Northwestern University | 2013-03-06 |
| Biomarkers in Patients With Advanced Rhabdomyosarcoma (NCT01668095) | Children's Oncology Group | 2012-08-01 |
| Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery (NCT01623869) | National Cancer Institute (NCI) | 2012-07-01 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma (NCT02507076) | Albert Einstein College of Medicine | 2012-04-01 |
| Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma (NCT01446809) | University of Washington | 2012-04-01 |
| Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (NCT01477021) | Fred Hutchinson Cancer Center | 2012-01-01 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma (NCT01462630) | Fox Chase Cancer Center | 2011-11-03 |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma (NCT01281865) | National Cancer Institute (NCI) | 2011-01-01 |
| Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery (NCT01206140) | National Cancer Institute (NCI) | 2010-10-01 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (NCT01154452) | National Cancer Institute (NCI) | 2010-06-01 |
| 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma (NCT01169350) | National Cancer Institute (NCI) | 2010-02-01 |
| Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma (NCT01055314) | National Cancer Institute (NCI) | 2010-01-01 |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (NCT01016015) | National Cancer Institute (NCI) | 2009-11-01 |
| Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery (NCT01553539) | Wake Forest University Health Sciences | 2009-10-01 |
| Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma (NCT00937495) | National Cancer Institute (NCI) | 2009-06-01 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (NCT00720174) | National Cancer Institute (NCI) | 2008-06-01 |
| Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis (NCT01014598) | Roswell Park Cancer Institute | 2007-12-04 |
| Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma (NCT00346164) | Children's Oncology Group | 2007-02-05 |
| Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) (NCT00330421) | National Cancer Institute (NCI) | 2006-06-01 |
| Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma (NCT00233948) | City of Hope Medical Center | 2006-03-01 |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma (NCT00245102) | National Cancer Institute (NCI) | 2005-09-01 |
| Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (NCT00112463) | National Cancer Institute (NCI) | 2005-01-07 |
| Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery (NCT00098579) | National Cancer Institute (NCI) | 2004-10-01 |
| CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor (NCT00087074) | National Cancer Institute (NCI) | 2004-06-01 |
| Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (NCT00084630) | National Cancer Institute (NCI) | 2004-05-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma (NCT00064324) | National Cancer Institute (NCI) | 2003-06-01 |
| BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma (NCT00022542) | National Cancer Institute (NCI) | 2001-06-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (NCT00004241) | National Cancer Institute (NCI) | 1999-10-01 |